CTRI/2017/12/010767进行中（未招募）未知
FOcal Radiotherapy and chemotherapy avoiding craniospinal irradiation in WNT subgroup medulloblastoma (FOR-WNT) Study
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Newly diagnosed WNT pathway medulloblastoma
- •Post surgery residual disease less than 1.5 cm2 on post operative MRI brain.
- •No evidence of metastatic disease in the brain, spine or cerebral spinal fluid (CSF) assessed by MRI of the brain and spine and a lumbar puncture for CSF cytology.
排除标准
- •Age Less than 3 and more than 16 years.
- •Molecular subgroup other than WNT pathway.
- •Post surgery residual disease more than 1.5cm2 on post-operative imaging
- •Evidence of any metastatic disease in the brain, spine or cerebral spinal fluid (CSF).
- •Previous history of radiotherapy or chemotherapy prior to study enrollment.
研究者
相似试验
进行中（未招募）
不适用
ow-doses radiotherapy and concomitant chemotherapy with pemetrexed in progression desease NSCLC: a dose-descalation phase II study - NDadvanced and/or metastatic NSCLCMedDRA version: 9.1Level: LLTClassification code 10059515Term: Non-small cell lung cancer metastaticEUCTR2008-003690-40-ITPOLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
进行中（未招募）
1 期
ChemoRadiotherapy with Or Without surgery followed by consolidation Durvalumab (CROWD): a phase IV feasibility trialStage III non-small cell lung cancerCTIS2024-511711-21-00Amsterdam UMC Stichting38
尚未招募
2 期
Combination of chemoTherapy aNd chemoradioTherapy for adenocarcinoma of the OESophagus and gastro-oesophageal junction with limited metastatic disease - TNT-OES-1 TRIAesophageal cancerNL-OMON49762Erasmus MC, Universitair Medisch Centrum Rotterdam20
招募中
不适用
Combination of chemoTherapy aNd chemoradioTherapy for adenocarcinoma of the OESophagus and gastro-oesophageal junction with oligometastatic diseaseNL-OMON23939Erasmus MC20
进行中（未招募）
1 期
Chemotherapy followed by chemoradiotherapy for metastatic esophageal cancerPatients (18 – 75 years) who are diagnosed with adenocarcinoma of the oesophagus or GOJ with a resectable primary tumour and de-novo synchronous oligometastatic disease.EUCTR2020-003605-55-NLErasmus MC - University Medical Centre20